NCT04278768 2026-03-19
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Curis, Inc.
Phase 1/2 Suspended
Clinical Trials
45 trialsNCT05969002 2026-03-18
Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias
National Institutes of Health Clinical Center (CC)
Completed
NCT03838926 2026-03-16
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals
Phase 1 Recruiting
NCT04347616 2026-03-16
NK4AML
Radboud University Medical Center
Phase 1/2 Terminated
NCT04588922 2026-03-16
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Phase 1/2 Recruiting
NCT04926285 2026-03-16
VEN-OM
University of Illinois at Chicago
Phase 1 Completed
NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT05748197 2026-03-10
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06459024 2026-03-10
IMPACT STREAM
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Recruiting
NCT07257419 2026-03-10
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04521231 2026-03-06
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Recruiting
NCT04416984 2026-03-04
ALPHA2
Allogene Therapeutics
Phase 1/2 Active not recruiting
NCT05283720 2026-03-03
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT06846606 2026-03-03
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics, Inc.
Phase 1 Active not recruiting
NCT06173518 2026-03-02
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
Phase 1 Recruiting
NCT07428486 2026-02-23
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07423104 2026-02-20
A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia
University of Rochester
Phase 2 Not yet recruiting
NCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT04094311 2026-02-17
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT06325748 2026-02-12
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
Phase 1 Active not recruiting
NCT06644183 2026-02-11
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06542250 2026-02-10
TITANium
AstraZeneca
Phase 1/2 Recruiting
NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT04809467 2026-02-04
topMIND
Incyte Corporation
Phase 1/2 Terminated
NCT04716452 2026-02-03
KNAN2001
Keystone Nano, Inc
Phase 1 Recruiting
NCT00709033 2026-01-30
ATECRAB
Baylor College of Medicine
Phase 1 Completed
NCT06660368 2026-01-29
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated
NCT05753501 2026-01-27
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Phase 1 Recruiting
NCT07366801 2026-01-26
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Recruiting
NCT04139434 2026-01-23
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Newave Pharmaceutical Inc
Phase 1 Completed
NCT06359002 2026-01-20
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
Byondis B.V.
Phase 1 Active not recruiting
NCT06768476 2026-01-16
AML
University of Pennsylvania
Phase 1 Active not recruiting
NCT05544968 2026-01-12
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
NCT07319793 2026-01-06
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Peking University People's Hospital
Phase NA Not yet recruiting
NCT01853631 2026-01-05
SAGAN
Baylor College of Medicine
Phase 1 Recruiting
NCT05199051 2026-01-05
AGORA-1
Centre Antoine Lacassagne
Phase 2 Active not recruiting
NCT07173595 2026-01-02
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05657652 2025-12-29
CAV Regimen for R/R Ph- B-ALL
The First Affiliated Hospital of Soochow University
Phase NA Recruiting
NCT07306832 2025-12-29
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
AbbVie
Phase 1 Not yet recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT07167381 2025-12-23
xDRIVE for Florida-based Cancer Patients
First Ascent Biomedical Inc.
Phase NA Recruiting
NCT04824794 2025-12-22
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Phase 1/2 Terminated